Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ: CORT )

69.27 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 580
Open 69.27
Bid (Size) 67.10 (1)
Ask (Size) 72.00 (2)
Prev. Close 69.27
Today's Range 69.27 - 69.27
52wk Range 22.00 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
From Corcept Therapeutics Incorporated
Via Business Wire
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
From Corcept Therapeutics Incorporated
Via Business Wire

Performance

YTD
+38.62%
+38.62%
1 Month
+16.48%
+16.48%
3 Month
+17.35%
+17.35%
6 Month
+44.13%
+44.13%
1 Year
+201.17%
+201.17%

More News

Read More
SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know
Via StockStory
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Interest Rates
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Investors seeking growth at a reasonable cost should explore CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
Via Chartmill
3 Biopharmaceutical Stocks Bucking the Sell-Off
Via MarketBeat
Topics World Trade
Exposures Product Safety Tariff
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4)
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Top stock movements in today's session.
Via Chartmill
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Via Benzinga
Why Is Corcept (CORT) Stock Soaring Today
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Monday's session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Via Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Mr. Cooper Group, Southern States Bancshares, Corcept Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Monday's pre-market session: top gainers and losers
Via Chartmill
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.